Europe is expected to be the Anxiety Disorders and Depression Treatment Market’s second-largest player, owing to significant investments in R&D for the advancement of antidepressant drugs. This, along with increased sales from anxiety-related products, is anticipated to drive growth throughout the forecast period.
The government’s goal of reducing the financial burden of these illnesses is likely to boost product requirements and ensure prompt anxiety and depression treatment.
Major depressive disorder (MDD) is the leading cause of chronic health-related burden among all mental health disorders. During the COVID-19 pandemic, several uncertain factors influencing mental health compiled, such as virus transmission, blockade and ban, public transportation constraints, school and business closures, and reduced social interaction, leading to a rise in the substantial threat of MDD and ramping up the health-related burden. As a result, the higher incidence would necessitate excessive consumption of antidepressant drugs, expanding market growth in Europe.
Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15808
Moreover, favorable reimbursement regulations in developed nations for medications and therapeutic approaches, combined with their high levels of success are expected to stimulate demand in this region during the forecast period. However, the high cost of this equipment and therapies, including anesthesia and hospitalization, has resulted in a shift in patient preference for drugs. Based on distribution channels in this region, the online channels category is considered to have the largest CAGR in the anxiety and depression drugs market in the coming years. Consumers are switching to such online sites due to the sheer shopping convenience they provide, such as the ability to order from home, receive discounts, and obtain doorstep delivery.
Key Takeaways
- The anxiety disorders and depression treatment market in the U.K to be worth US$ 665.5 Million by 2032, generating a dollar opportunity of US$ 141.2 Million
- European market for anxiety disorders and depression treatment is presumed to grow at a CAGR of 2.4%.
- In Europe, Poland and Romania have the lowest reported incidence of anxiety and depression.
- Greece has the highest depression prevalence, preceded by Spain and Portugal.
- In the Anxiety Disorders and Depression Treatment Market, the depression segment is taking central place.
Competitive Landscape
Because of technological advancements, a large number of players are based in developing nations. However, because of modern connectivity, these participants have also penetrated emerging economies and are attempting to build an industry in these countries as well.
Inquire Before Buying Research Report: https://www.futuremarketinsights.com/ask-question/rep-gb-15808
Market players intend to invest in technological innovations, mergers and acquisitions, new product launches, and study and development. Furthermore, they are likely to place a stronger emphasis on investing in novel developments and items to widen their market reach.
The key companies operating in the Anxiety Disorders and Depression Treatment Market include Pfizer Inc, H. Lundbeck A/S, Glaxo SmithKline pharmaceuticals ltd, Merck & Co., Inc, Eli Lilly & Company, AstraZeneca, H. Lundbeck A/S, Bristol-Myers Squibb, Johnson & Johnson, AbbVie Inc., Sanofi, Novartis AG, Forest Laboratories, Inc., Alembic pharma, Janssen Pharmaceutical N.V., and Cadent Therapeutics.
Recent Developments
- The European Medicines Agency (EMA) approved H. Lundbeck A/submission S’s for Vyepti for evaluation of the Marketing Authorization Application in December 2020. (MAA). The application requests that Vyepti be made available to European residents who undergo from migraine and are eligible for preventive care therapy. Vyepti’s objective is to avoid calcitonin gene-related peptide (CGRP) from interacting with its receptor, thereby preventing migraine attacks.
- Novartis announced in December 2020 that it would acquire Cadent Therapeutics for a total consideration of up to US$ 770 million. Novartis will be able to profit from Cadent’s entire neuroscience portfolio as a result of the acquisition, increasing its market share in the field of mental health.
- HMNC Brain Health reported encouraging top-line results from its Phase 2 Proof-of-Concept investigator-initiated trial of its oral prolonged-release composition of ketamine (KET01) in Treatment-Resistant Depression in March 2022. (TRD).
Use promo code ->> FMITODAY to get a flat 20% discount
Key Segments Covered in Anxiety Disorders and Depression Treatment Market Survey
Anxiety Disorders and Depression Treatment Market by Drug Class:
- Antidepressants
- Anxiolytics
- Anticonvulsants
- Noradrenergic Agents
- Atypical Antipsychotics
Anxiety Disorders and Depression Treatment Market by Indication:
- Anxiety
- Depression
Anxiety Disorders and Depression Treatment Market by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
